Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALSP Orchid Acquisition Corp IALOR · Entity 11497 | Director | November 18, 2021 | November 18, 2021 |
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Director | March 11, 2026 | March 13, 2026 |
| Xencor IncXNCR · Entity 4487 | Director | June 14, 2017 | June 16, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALSP Orchid Acquisition Corp I
Report date November 18, 2021 · Filed November 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities are beneficially ownedSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2021-11-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
ENANTA PHARMACEUTICALS INC
Report date March 11, 2026 · Filed March 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2036-03-11 | Direct | 20,000 |
Reported balance
After 2026-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-11 · Grant · Acquired 20,000 · Balance 20,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.
Xencor Inc
Report date June 14, 2017 · Filed June 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,578 |
Ending reported balance
After 2017-06-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-06-14 · Sale · Disposed 19,698 · Balance 48,880 Row 2 · 2017-06-14 · Sale · Disposed 302 · Balance 48,578 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 23, 2024
Section 16 reporting ended · disclosed 2024-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-01-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-23 · Disposition to issuer · Disposed 6,021 · Balance 11,252 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 4,444 · Balance 6,808 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 6,808 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-23 · Disposition to issuer · Disposed 7,520 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $64.14 · Expires 2029-01-16 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-23 · Disposition to issuer · Disposed 11,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2026 Filed Mar 13, 2026 20:14 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0002064832-26-000138 · form4.xml · derivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-03-11 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 21:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 15,700 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001062993-25-005502 · form4.xml · derivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2035-03-13 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:12 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 15,700 | $0.00 Strike: $15.66 | $0.00 |
DisclosureSEC source: 0001062993-24-006036 · form4.xml · derivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-03-06 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 11,000 | Not disclosed Strike: $64.14 | Not disclosed |
DisclosureSEC source: 0001140361-24-003535 · form4.xml · derivative · entry 6 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2029-01-16 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7 · price: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,520 | Not disclosed Strike: $45.66 | Not disclosed |
DisclosureSEC source: 0001140361-24-003535 · form4.xml · derivative · entry 5 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,000 | Not disclosed Strike: $3.65 | Not disclosed |
DisclosureSEC source: 0001140361-24-003535 · form4.xml · derivative · entry 4 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 6,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003535 · form4.xml · nonDerivative · entry 3 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 4,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003535 · form4.xml · nonDerivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,808 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 6,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003535 · form4.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,252 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 18:16 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 6,808 | $58.75 | $399,970.00 |
DisclosureSEC source: 0001628280-24-000292 · wk-form4_1704323789.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,273 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:15 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 10,800 | $0.00 Strike: $47.72 | $0.00 |
DisclosureSEC source: 0001062993-23-006087 · form4.xml · derivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2033-03-02 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2023), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2024 annual meeting of stockholders. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 7,520 | $0.00 Strike: $45.66 | $0.00 |
DisclosureSEC source: 0001214659-23-001041 · marketforms-58264.xml · derivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 4,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001041 · marketforms-58264.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,465 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 16:15 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001214659-22-010296 · marketforms-56893.xml · derivative · entry 4 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option vested and became exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 16:15 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 4,893 | $85.96 | $420,612.07 |
DisclosureSEC source: 0001214659-22-010296 · marketforms-56893.xml · nonDerivative · entry 3 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,021 F2 · price: This transaction was executed in multiple trades at prices ranging from $85.60 to $86.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 16:15 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 5,107 | $85.04 | $434,287.02 |
DisclosureSEC source: 0001214659-22-010296 · marketforms-56893.xml · nonDerivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,914 F1 · price: This transaction was executed in multiple trades at prices ranging from $84.55 to $85.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 16:15 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 10,000 | $27.00 | $270,000.00 |
DisclosureSEC source: 0001214659-22-010296 · marketforms-56893.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 21:52 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $25.58 | $0.00 |
DisclosureSEC source: 0001062993-22-008344 · form4.xml · derivative · entry 6 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 21:52 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 807 | $69.52 | $56,102.64 |
DisclosureSEC source: 0001062993-22-008344 · form4.xml · nonDerivative · entry 5 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $69.39 to $70.07, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 21:52 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,210 | $68.66 | $151,738.60 |
DisclosureSEC source: 0001062993-22-008344 · form4.xml · nonDerivative · entry 4 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $68.509 to $68.76, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 21:52 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 307 | $67.23 | $20,639.61 |
DisclosureSEC source: 0001062993-22-008344 · form4.xml · nonDerivative · entry 3 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $67.005 to $67.47, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 21:52 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,676 | $66.70 | $178,489.20 |
DisclosureSEC source: 0001062993-22-008344 · form4.xml · nonDerivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,324 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $66.28 to $66.99, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 21:52 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 6,000 | $25.58 | $153,480.00 |
DisclosureSEC source: 0001062993-22-008344 · form4.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:40 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $68.22 | $0.00 |
DisclosureSEC source: 0001062993-22-007001 · form4.xml · derivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2032-03-03 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 3, 2022), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2023 annual meeting of stockholders. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 3,688 | $0.00 Strike: $124.31 | $0.00 |
DisclosureSEC source: 0001214659-22-000848 · marketforms-55078.xml · derivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688 Underlying: Common Stock · 3,688 shares Expires 2032-01-13 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-000848 · marketforms-55078.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,021 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:06 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001214659-21-003985 · marketforms-52198.xml · derivative · entry 4 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:06 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 282 | $180.00 | $50,760.00 |
DisclosureSEC source: 0001214659-21-003985 · marketforms-52198.xml · nonDerivative · entry 3 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:06 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,968 | $176.70 | $347,746.98 |
DisclosureSEC source: 0001214659-21-003985 · marketforms-52198.xml · nonDerivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,757 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $176.25 to $177.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:06 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 2,250 | $6.78 | $15,255.00 |
DisclosureSEC source: 0001214659-21-003985 · marketforms-52198.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 23:17 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $49.92 | $0.00 |
DisclosureSEC source: 0001177648-21-000011 · edgar.xml · derivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-03-02 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 17:08 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001214659-21-001204 · marketforms-51347.xml · derivative · entry 5 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 17:08 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 218 | $194.38 | $42,374.84 |
DisclosureSEC source: 0001214659-21-001204 · marketforms-51347.xml · nonDerivative · entry 4 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 17:08 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 300 | $192.32 | $57,694.50 |
DisclosureSEC source: 0001214659-21-001204 · marketforms-51347.xml · nonDerivative · entry 3 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F3 · price: This transaction was executed in multiple trades at prices ranging from $192.18 to $192.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 17:08 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,732 | $190.50 | $329,948.25 |
DisclosureSEC source: 0001214659-21-001204 · marketforms-51347.xml · nonDerivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,993 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $190.15 to $191.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 17:08 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 2,250 | $6.78 | $15,255.00 |
DisclosureSEC source: 0001214659-21-001204 · marketforms-51347.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 18:17 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 2,155 | $0.00 Strike: $214.47 | $0.00 |
DisclosureSEC source: 0001214659-21-000681 · marketforms-50976.xml · derivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155 Underlying: Common Stock · 2,155 shares Expires 2031-01-14 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 18:17 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-000681 · marketforms-50976.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · derivative · entry 9 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 2,250 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1 | $248.96 | $248.96 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · nonDerivative · entry 8 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 357 | $248.28 | $88,634.21 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · nonDerivative · entry 7 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F6 · price: This transaction was executed in multiple trades at prices ranging from $247.90 to $248.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 710 | $247.63 | $175,817.37 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · nonDerivative · entry 6 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,358 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F5 · price: This transaction was executed in multiple trades at prices ranging from $246.88 to $247.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 257 | $246.27 | $63,292.34 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · nonDerivative · entry 5 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,068 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F4 · price: This transaction was executed in multiple trades at prices ranging from $245.855 to $246.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 589 | $244.97 | $144,286.98 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · nonDerivative · entry 4 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,325 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F3 · price: This transaction was executed in multiple trades at prices ranging from $244.54 to $245.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 287 | $244.05 | $70,041.20 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · nonDerivative · entry 3 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,914 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $243.50 to $244.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 49 | $240.93 | $11,805.57 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · nonDerivative · entry 2 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,201 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 2,250 | $6.78 | $15,255.00 |
DisclosureSEC source: 0001214659-20-010486 · marketforms-50635.xml · nonDerivative · entry 1 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 16:03 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001214659-20-007045 · marketforms-49442.xml · derivative · entry 6 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 2,250 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F5 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 16:03 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 100 | $131.16 | $13,116.00 |
DisclosureSEC source: 0001214659-20-007045 · marketforms-49442.xml · nonDerivative · entry 5 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 16:03 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 110 | $127.58 | $14,033.90 |
DisclosureSEC source: 0001214659-20-007045 · marketforms-49442.xml · nonDerivative · entry 4 CARTER BRUCE L A · CIK 0001225503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2020 F4 · price: This transaction was executed in multiple trades at prices ranging from $127.58 to $127.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.